Answers are grounded in this paper and cite their sources.
The Keynote-522 trial recently demonstrated benefit of adding an immune checkpoint inhibitor (ICI) (pembrolizumab) to paclitaxel-carboplatin epirubicin-cyclophosphamide (PC-EC) combination chemotherapy in the neoadjuvant setting for patients with early triple negative breast cancer.1 Haemophagocytic lymphohistiocytosis (HLH) is a cytokine-mediated hyperinflammation syndrome, which causes fever, pancytopenia and haemophagocytosis and is often fatal. The H-score offers a dynamic prediction of the probability of HLH using nine variables.2 We present two cases of ICI-mediated HLH in patients receiving PC-EC pembrolizumab in the neoadjuvant setting for triple negative breast cancer. Patient 1 is a 61-year-old lady who was referred to our regional acute ICI toxicity service following an acute admission to a local hospital with significant fevers (39.0°C), myalgia, extreme fatigue and a rash. She had up to that point completed 4 cycles of weekly PC Pembrolizumab. She was initially treated with empirical intravenous antimicrobial therapy and standard sepsis management for 4 days. Despite this, she suffered rapid deterioration with continued fevers, haemodynamic instability, respiratory failure, liver failure and acute kidney injury necessitating intensive care management and organ support at Day 5.
No takes yet. Share an insight, caveat, or question.
Cooksley et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: